Corvus Pharmaceuticals (CRVS) Profit After Tax (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Profit After Tax of -$13.9 million for Q1 2026, down 191.43% year-over-year from $15.2 million in Q1 2025, and down 37.07% quarter-over-quarter from -$10.2 million in Q3 2025.
Corvus Pharmaceuticals (CRVS) Profit After Tax (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Profit After Tax history runs 12 years deep, the most recent figure standing at -$13.9 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 191.43% year-over-year to -$13.9 million; the TTM figure through Mar 2026 stood at -$16.8 million (up 50.93% YoY), while the FY2025 annual figure was -$102.1 million, down 12.78% from the prior year.
- Profit After Tax for Q1 2026 stood at -$13.9 million, down from -$10.2 million in the prior quarter.
- The five-year high for Profit After Tax was $15.2 million in Q1 2025, with the low at -$39.6 million in Q3 2024.
- The 5-year median for Profit After Tax is -$7.9 million (2023), against an average of -$8.7 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax plunged 560.0% in 2024, then jumped 367.09% in 2025.
- Corvus Pharmaceuticals' Profit After Tax stood at -$6.8 million in 2022, then increased by 14.95% to -$5.7 million in 2023, then sank by 589.42% to -$39.6 million in 2024, then surged by 74.35% to -$10.2 million in 2025, then slumped by 37.07% to -$13.9 million in 2026.
- Business Quant data shows CRVS's Profit After Tax at -$13.9 million in Q1 2026, -$10.2 million in Q3 2025, and -$8.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | -18.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.13 Mn |
| Mar 31, 2026 | -13.92 Mn |
| Sep 30, 2025 | -10.16 Mn |
| Jun 30, 2025 | -8.00 Mn |
| Mar 31, 2025 | 15.23 Mn |
| Sep 30, 2024 | -39.60 Mn |
| Jun 30, 2024 | -4.26 Mn |
| Mar 31, 2024 | -5.70 Mn |
| Dec 31, 2023 | -5.74 Mn |
| Sep 30, 2023 | -6.00 Mn |
| Jun 30, 2023 | -6.50 Mn |
| Mar 31, 2023 | -7.87 Mn |
| Dec 31, 2022 | -6.75 Mn |
| Sep 30, 2022 | -14.83 Mn |
| Jun 30, 2022 | -8.36 Mn |
| Mar 31, 2022 | -8.30 Mn |
| Dec 31, 2021 | -10.57 Mn |
| Sep 30, 2021 | -10.69 Mn |
| Jun 30, 2021 | -11.75 Mn |
| Mar 31, 2021 | -11.58 Mn |